
Jan 9 (Reuters) - Camurus AB CAMX.ST:
CAMURUS ANNOUNCES FDA ACCEPTANCE OF NDA RESUBMISSION FOR OCLAIZ™ FOR THE TREATMENT OF ACROMEGALY
CAMURUS AB - PDUFA TARGET ACTION DATE SET FOR 10 JUNE 2026
CAMURUS AB: PRODUCT RECEIVED MARKETING AUTHORIZATION IN THE EU AND UK IN 2025 UNDER THE PRODUCT NAME OCZYESA, PRODUCT LAUNCH INITIATED IN THE EU